In the emerging era of disease‐modifying anti‐amyloid therapy for AD, its correlation with cognitive decline may be utilized in the future as a biomarker for therapy monitoring, similar to how we use NfL in multiple sclerosis therapy. The gene discussed is NEFL; the disease is multiple sclerosis.